Health
Ultrapotent compound may help treat C. diff, reduce recurrence – Medical Xpress
Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.
Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.
Only two antibiotics, vancomycin and fidaxomicin, are FDA approved for the treatment of C. diff, but even these therapies suffer from high treatment failure and recurrence.
Now, Purdue University innovators have advanced novel compounds they developed to help treat patients with C. diff, one of only four bacteria considered an urgent threat by the Centers for Disease Control and Preventio…
-
General24 hours agoFallout from Ned Kelly’s last stand haunted families for generations
-
General22 hours agoTasmanian boy left homeless due to child protection department’s ‘gross negligence’, family member says
-
Business24 hours agoHow to make $5,000 a month in passive income
-
Noosa News19 hours agoTownsville remembers Jennifer Board, four years on from tragic death